Johnson & Johnson announced definitive agreement to acquire Cougar Biotechnology. The company will initiate a tender offer to buy all outstanding shares of Cougar Biotechnology at $43 per share. The Boards of both Johnson & Johnson and Cougar Biotechnology have approved the transaction. The deal is expected to close in the third quarter of 2009.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
BASF sells a majority stake in its coatings business to the investor Carlyle.
Compelling solutions through strategic partnerships
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
